Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Andreeff

Showing results (311-320 of 315) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 315 results.
American Journal of Hematology|July 10, 2001
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemiaS Bibawi, D Abi-Said, L Fayad, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Blood|February 7, 2001
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationS Giralt, P F Thall, I Khouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancerZ Rahman, J Kavanagh, R Champlin, et al.
Cancer Research|July 1, 1996
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendationsW T Beck, T M Grogan, C L Willman, et al.
Pageof 32

Showing results (311-320 of 315) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 315 results.
American Journal of Hematology|July 10, 2001
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemiaS Bibawi, D Abi-Said, L Fayad, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Blood|February 7, 2001
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationS Giralt, P F Thall, I Khouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancerZ Rahman, J Kavanagh, R Champlin, et al.
Cancer Research|July 1, 1996
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendationsW T Beck, T M Grogan, C L Willman, et al.
Pageof 32